Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2681-2691

  Bonner, James A ^a   Sloan, Jeff A ^a   Shanahan, Thomas G ^a   Brooks, Burke J ^a   Marks, Randolph S ^a   Krook, James E ^a   Gerstner, James B ^a   Maksymiuk, Andrew ^a   Levitt, Ralph ^a   Mailliard, James A ^a   Tazelaar, Henry D ^a   Hillman, Shauna ^a   Jett, James R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; ESOPHAGITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032880527     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2681     Document Type: Article

References (33)

1. Morstyn G, Russo A, Carney DN, et al: Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines. J Natl Cancer Inst 73:801-807, 1984
2. Turrisi AT III, Glover DJ, Mason BA: A preliminary report: Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 15:183-187, 1988
3. Turrisi A, Wagner H, Glover D, et al: Limited small cell lung cancer (LSCLC): Concurrent BID thoracic radiotherapy (TRT) with platinum-etoposide (PE) - An ECOG study. Proc Am Soc Clin Oncol 9:230, 1990 (abstr)
4. Johnson DH, Kim K, Sause W, et al: Cisplatin (P) & etoposide (E) + thoracic radiotherapy (TRT) administered once or twice daily (BID) in limited stage (LS) small cell lung cancer (SCLC): Final report of Intergroup Trial 0096. Proc Am Soc Clin Oncol 15:374, 1996 (abstr)
5. Turrisi AT III, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
6. Frytak S, Shaw EG, Eagan RT, et al: Hyperfractionated thoracic radiotherapy (HTRT) and infusion cisplatin based chemotherapy (CT) for small cell lung cancer (SCLC): A preliminary report. Proc Am Soc Clin Oncol 8:239, 1989 (abstr)
7. Frytak S, Shaw EG, Jett JR, et al: Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. Am J Clin Oncol 19:193-198, 1996
8. Wang CC, Suit HD, Blitzer PH: Twice-a-day radiation therapy for supraglottic carcinoma. Int J Radiat Oncol Biol Phys 12:3-7, 1986
9. Liengswangwong V, Bonner JA, Shaw EG, et al: Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 12:496-502, 1994
10. Eagan RT, Fleming TR, Schoonover V: Evaluation of response criteria in advanced lung cancer. Cancer 44:1125-1128, 1979
11. Miller RC, Bonner JA, Kline RW: Impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfaces. Int J Radiat Oncol Biol Phys 41:707-713, 1998
12. National Cancer Institute: National Cancer Institute Common Toxicity Criteria Guidelines. Bethesda, MD, National Cancer Institute, 1995
13. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
14. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, Lawrence Erlbaum Associates, 1988, pp 467-514
15. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 135:185-207, 1972
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Caplan RJ, Pajak TF, Cox JD: Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys 29:1183-1186, 1994
18. Gelman R, Gelber R, Henderson IC, et al: Improved methodology for analyzing local and distant recurrence. J Clin Oncol 8:548-555, 1990
19. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
20. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
21. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
22. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA, Lifetime Learning Publications, 1982
23. Bonner JA, McGinnis WL, Stella PJ, et al: The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: Results of a North Central Cancer Treatment Group phase III study. Cancer 82:1037-1048, 1998
24. Levin VA, Maor MH, Thall PF, et al: Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 33:357-364, 1995
25. Peters LJ, Ang KK: The role of altered fractionation in head and neck cancers. Semin Radiat Oncol 2:180-194, 1992
26. Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131-146, 1988
27. Marks LB, Dewhirst M: Accelerated repopulation: Friend or foe? Exploiting changes in tumor growth characteristics to improve the "efficiency" of radiotherapy. Int J Radiat Oncol Biol Phys 21:1377-1383, 1991
28. Gasinska A, Kolodziejski L, Biesaga B: Tumour cell kinetics as prognostic factor in surgically-treated-non-small cell lung cancer. Lung Cancer 18:159-170, 1997
29. Bitran JD, Golomb HM, Little AG, et al: Lung Cancer: A Comprehensive Treatise. Orlando, FL, Grune & Stratton, 1988, pp 36-39
30. Costa A, Silvestrini R, Mochen C, et al: P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer 73:914-919, 1996
31. Vescio RA, Connors KM, Bordin GM, et al: The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095-6099, 1990
32. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993
33. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912-918, 1987